Besides TNBC cells, FZU-00,003 also showed strong survival inhibition effects in other subtypes of breast cancer (Fig 1C), indicating FZU-00,003 may also be effective in treating luminal and HER2 positive breast cancers through other mechanisms since KLF5 is lowly expressed in these subtypes of breast cancer cells 18. Here, ERBB2 is linked to breast carcinoma.